Perpetual Ltd grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 4.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,354 shares of the medical research company’s stock after buying an additional 300 shares during the quarter. Perpetual Ltd’s holdings in Amgen were worth $1,267,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Bogart Wealth LLC increased its position in Amgen by 13.8% in the second quarter. Bogart Wealth LLC now owns 3,181 shares of the medical research company’s stock worth $548,000 after purchasing an additional 385 shares during the period. Intl Fcstone Inc. acquired a new stake in Amgen in the second quarter worth about $1,769,000. Gs Investments Inc. acquired a new stake in Amgen in the second quarter worth about $2,119,000. Lord Abbett & CO. LLC acquired a new stake in Amgen in the second quarter worth about $14,175,000. Finally, United Bank VA increased its position in Amgen by 7.4% in the second quarter. United Bank VA now owns 28,581 shares of the medical research company’s stock worth $4,923,000 after purchasing an additional 1,960 shares during the period. Institutional investors own 78.62% of the company’s stock.
In other news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Insiders have sold a total of 8,575 shares of company stock worth $1,509,339 in the last quarter. 0.19% of the stock is currently owned by company insiders.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. During the same quarter in the previous year, the business posted $3.02 EPS. Amgen’s revenue for the quarter was down .7% on a year-over-year basis. analysts forecast that Amgen, Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen declared that its board has authorized a stock buyback plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is 41.63%.
AMGN has been the subject of a number of research reports. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective for the company in a research report on Friday, October 27th. Bank of America lifted their price objective on Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday, October 5th. Barclays lifted their price objective on Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Oppenheimer reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Finally, Royal Bank of Canada initiated coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $190.22.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2017/12/17/perpetual-ltd-increases-stake-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.